Beam Therapeutics Inc. - COMMON STOCK (BEAM)

Historical Holders from Q1 2020 to Q3 2025

Symbol: BEAM on Nasdaq
Type / Class: Equity / COMMON STOCK
Shares outstanding: 101,224,395
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 106,522,701
Holdings value: $2,585,111,564
% of all portfolios: 0%
Number of holders: 210
Number of buys: 111
Number of sells: -89
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Beam Therapeutics Inc. - COMMON STOCK (BEAM)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
FMR LLC	13.6%	-9.3%	$334,113,385	-$31,963,105	13,766,517	-8.7%	FMR LLC	30 Sep 2025
ARK Investment Management LLC	10.35%	+30%	$223,401,540	+$83,244,155	10,410,137	+59%	ARK Investment Management LLC	31 Jul 2025
Farallon Capital Partners, L.P.	9.99%	+0.9%	$196,567,436	+$34,174,321	9,972,980	+21%	Dapice Joshua J.	31 Mar 2025
BlackRock, Inc.	7.5%		$147,823,620		7,499,930		BlackRock, Inc.	31 Mar 2025
ARCH Venture Fund IX, L.P.	4.6%	-17%	$90,680,723		4,600,747	0%	Robert Nelsen	31 Mar 2025

Institutional Holders of Beam Therapeutics Inc. - COMMON STOCK (BEAM)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	106,522,701	$2,585,111,564	-$9,743,415	$14,154,264	$22,092,981	$24.27	210
2025 Q2	108,325,993	$1,842,599,951	+$102,159,924	$33,890,724	$11,320,155	$17.01	213
2025 Q1	101,329,623	$1,984,124,636	+$387,248,348	$6,026,958	$8,290,485	$19.53	234
2024 Q4	81,429,029	$2,019,888,804	+$52,922,730	$3,524,080	$5,823,040	$24.8	228
2024 Q3	78,929,001	$1,933,839,851	+$32,128,779	$5,679,100	$10,738,350	$24.5	217
2024 Q2	77,540,507	$1,816,892,862	+$138,460,483	$5,447,475	$5,934,899	$23.43	210
2024 Q1	70,332,894	$2,323,064,829	+$51,308,447	$25,665,592	$10,265,648	$33.04	217
2023 Q4	68,925,790	$1,876,215,663	+$46,457,918	$5,090,140	$8,073,452	$27.22	183
2023 Q3	67,439,160	$1,621,864,483	+$72,305,572	$9,057,230	$8,006,245	$24.05	190
2023 Q2	64,198,552	$2,049,551,170	+$123,991,732	$5,444,065	$13,892,743	$31.93	191
2023 Q1	60,372,846	$1,848,161,788	+$134,989,244	$13,601,404	$11,653,972	$30.62	205
2022 Q4	55,910,182	$2,186,652,051	+$42,258,811	$14,967,397	$7,493,476	$39.11	205
2022 Q3	54,633,598	$2,601,918,929	-$6,231,369	$11,204,000	$34,544,400	$47.64	214
2022 Q2	54,764,598	$2,088,902,541	+$192,782,034	$9,400,000	$9,600,000	$38.71	191
2022 Q1	49,225,196	$2,820,671,022	+$201,996,007	$22,249,000	$18,754,000	$57.3	230
2021 Q4	45,547,893	$3,629,719,477	-$39,454,291	$16,894,000	$16,091,000	$79.69	224
2021 Q3	45,176,306	$3,933,867,577	-$43,842,015	$23,310,000	$19,177,000	$87.01	223
2021 Q2	45,484,033	$5,854,372,685	+$342,578,385	$35,370,000	$50,288,000	$128.71	223
2021 Q1	43,012,900	$3,436,702,468	+$478,571,473	$48,726,000	$59,389,280	$80.04	203
2020 Q4	36,917,618	$3,014,269,128	+$632,622,766	$28,663,000	$14,123,000	$81.64	152
2020 Q3	29,525,955	$726,945,347	+$39,624,702			$24.62	84
2020 Q2	27,707,853	$775,554,484	+$34,103,632			$28	70
2020 Q1	26,888,544	$483,990,454	+$483,990,450			$18	60